Kura Oncology announces clinical collaboration to evaluate ziftomenib

Kura Oncology and The Leukemia & Lymphoma Society announced a clinical collaboration to evaluate Kura‘s menin inhibitor, ziftomenib, in combination with chemotherapy in pediatric patients with relapsed/refractory KMT2A-rearranged, NUP98-rearranged or NPM1-mutant acute leukemia. In partnership with the PedAL Initiative, LLS will serve as the coordinating sponsor in North America and the Princess Maxima Center for Pediatric Oncology in Utrecht, the Netherlands, will serve as the coordinating sponsor in Europe. PedAL is a pioneering global master clinical trial for Pediatric Acute Leukemia, founded and led by LLS, which aims to advance more effective, safer treatments with fewer long-term side effects, for children with blood cancer. Under the terms of the agreement, LLS and the Princess Maxima Center will sponsor the Phase 1 study of ziftomenib in pediatric patients with acute leukemias. Kura will supply LLS and the Princess Maxima Center with ziftomenib for the study.